Hikma stock gets a new R&D investor series in October

Published on 10/04/2026 at 23:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma stock was last at GBp 1,580 on October 2, while H1 2026 revenue rose 4.2 percent to USD 1.73 billion. Management kept 2026 operating profit guidance at USD 720-770 million.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen — Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma stock (ISIN GB00B0LCW083) was last at GBp 1,580 on the London Stock Exchange on October 2, 2026 at 4:35 p.m. London time, up 0.57 percent on the session. The company is preparing an R&D investor seminar series, with the first event scheduled for October 20, 2026, according to Hikma in its September 22, 2026 release.

H1 revenue reached USD 1.73 billion

Hikma's first-half performance provides the financial anchor for the October investor events. H1 2026 revenue rose 4.2 percent to USD 1.73 billion, while net income fell 6.3 percent to USD 223.0 million and earnings per share declined to USD 1.03 from USD 1.08 in H1 2025, according to Simply Wall St.

The operating mix was more constructive than the bottom line. Core operating profit increased 9 percent to USD 405 million, while reported operating profit rose 30 percent to USD 336 million and operating cash flow climbed 33 percent to USD 214 million in the six months ended June 30, 2026, according to SC Group.

Consensus target is GBp 2,085.83

MarketBeat lists a Buy consensus from six analysts, with a high target of GBp 2,400, a low target of GBp 1,870 and an average target of GBp 2,085.83. Against the October 2 price of GBp 1,580, the average target stands 32.0 percent above the reference price according to MarketBeat.

That valuation view sits alongside a more cautious earnings profile. Hikma reiterated 2026 group revenue growth guidance of 2 percent to 4 percent and core operating profit guidance of USD 720 million to USD 770 million, while the H1 figures showed higher revenue but lower net income.

October events center on the pipeline

The October 20 seminar will cover group R&D, respiratory products, nasal products, semi-solids and liquids. Hikma also scheduled sessions on solid orals for November 24, 2026, and injectables for December 16, 2026, according to Hikma.

The company has also named Rebecca Hall as its next chief financial officer. She will join in the first quarter of 2027, replacing Khalid Nabilsi, who is scheduled to leave the board on December 31, 2026, according to Hikma.

Hikma stock stays below its yearly high

Hikma stock was last at GBp 1,580 on October 2, 2026, with a 52-week range of GBp 1,187 to GBp 1,865 and a market capitalization of GBP 3.3 billion. Trading volume was 291,397 shares, giving investors a dated market view as the company moves toward its October pipeline event.